Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- Generic Makers Should Shift to Biologics Biz for Survival: MHLW Official
July 11, 2018
- MHLW Official Expounds on “Authorized Biosimilar” Pricing, 50% Generic Rule Applies for “Biosame” Products
July 11, 2018
- Cabinet OKs FY2019 Budget Guidelines, Allows Request for 600 Billion Yen Social Security Cost Rise
July 11, 2018
- Prices for High-Cost Techs Will Settle Down as They Penetrate Market with Public Health Coverage: MHLW Bureau Chief
July 10, 2018
- Tokyo Govt to Launch Support Program for Drug Discovery Startups to Solve Obstacles to Fundraising, IP Strategy
July 10, 2018
- Reduce Dose, or Discontinue Biologics for Patients with Low RA Disease Activity: Report
July 9, 2018
- Govt Dodges Lawmaker Inquiry on Timing of 2019 Drug Price Revision
July 9, 2018
- LDP Lawmakers to Sort Out Life Science Issues over This Summer
July 6, 2018
- Council OKs Public Knowledge-Based Submissions for New Azathioprine, Temozolomide Indications
July 5, 2018
- Govt Likely to Allow 600 Billion Yen Rise for FY2019 Social Security Budget Request
July 4, 2018
- Several Brand-Name Drug Makers Intend to Withdraw “G1” LLPs
July 4, 2018
- LDP Lawmakers Launch New Study Group on Life Science Industry
July 3, 2018
- MHLW OKs 1st Pfizer Biosimilar, Add’l Indications and Dosages
July 3, 2018
- MHLW Approves Entyvio, Imfinzi, Lynparza Breast Cancer Use, and More
July 3, 2018
- PMDA Reveals First 2 Cases of MID-NET Regulatory Use
July 2, 2018
- LDP’s Patch Panel Boots Up with Bigwig Noda as Chairman
June 28, 2018
- MHLW to Remove Pregnancy Contraindication for 3 Immunosuppressants
June 27, 2018
- Ryukaikon Working Group to Discuss Rebates Offered to Make Up for Higher Invoice Prices
June 26, 2018
- New LDP Study Group to Kick Off with Focus on Innovation in Life Science
June 25, 2018
- PMDA Wants to Increase Safety Staffers to 270 by FY2023: Official
June 21, 2018
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…